ResearcherShanghai Medical College of Fudan UniversityNo recent work listed

Liang Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9082-940X; OpenAlex author ID A5074191676. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 12

Papers, trials and grants by year

2023: 2 papers

Papers 2

LDHA is a prognostic biomarker on the immune response in pancreatic adenocarcinoma and associated with m6A modification. Last author DOI 10.1007/s00432-022-04400-8 ↗
Metabolic reprogramming of cancer-associated fibroblasts in pancreatic cancer contributes to the intratumor heterogeneity of PET-CT. Co-author DOI 10.1016/j.csbj.2023.04.003 ↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Xianjun Yu · 2 shared papers, 2023 · strength 0.38
- Paper LDHA is a prognostic biomarker on the immune response in pancreatic adenocarcinoma and associated with m6A modification. DOI 10.1007/s00432-022-04400-8 ↗
- Paper Metabolic reprogramming of cancer-associated fibroblasts in pancreatic cancer contributes to the intratumor heterogenei… DOI 10.1016/j.csbj.2023.04.003 ↗
Bo Zhang · 1 shared paper, 2023 · strength 0.20
- Paper LDHA is a prognostic biomarker on the immune response in pancreatic adenocarcinoma and associated with m6A modification. DOI 10.1007/s00432-022-04400-8 ↗
Jin Xu · 1 shared paper, 2023 · strength 0.20
- Paper LDHA is a prognostic biomarker on the immune response in pancreatic adenocarcinoma and associated with m6A modification. DOI 10.1007/s00432-022-04400-8 ↗
Zhen Tan · 1 shared paper, 2023 · strength 0.20
- Paper LDHA is a prognostic biomarker on the immune response in pancreatic adenocarcinoma and associated with m6A modification. DOI 10.1007/s00432-022-04400-8 ↗
Xiaoqi Mao · 1 shared paper, 2023 · strength 0.18
- Paper Metabolic reprogramming of cancer-associated fibroblasts in pancreatic cancer contributes to the intratumor heterogenei… DOI 10.1016/j.csbj.2023.04.003 ↗
Zengli Fang · 1 shared paper, 2023 · strength 0.18
- Paper Metabolic reprogramming of cancer-associated fibroblasts in pancreatic cancer contributes to the intratumor heterogenei… DOI 10.1016/j.csbj.2023.04.003 ↗
Qingcai Meng · 1 shared paper, 2023 · strength 0.18
- Paper Metabolic reprogramming of cancer-associated fibroblasts in pancreatic cancer contributes to the intratumor heterogenei… DOI 10.1016/j.csbj.2023.04.003 ↗
Rong Tang · 1 shared paper, 2023 · strength 0.18
- Paper Metabolic reprogramming of cancer-associated fibroblasts in pancreatic cancer contributes to the intratumor heterogenei… DOI 10.1016/j.csbj.2023.04.003 ↗
Jie Hua · 1 shared paper, 2023 · strength 0.18
- Paper Metabolic reprogramming of cancer-associated fibroblasts in pancreatic cancer contributes to the intratumor heterogenei… DOI 10.1016/j.csbj.2023.04.003 ↗
Wei Wang · 1 shared paper, 2023 · strength 0.18
- Paper Metabolic reprogramming of cancer-associated fibroblasts in pancreatic cancer contributes to the intratumor heterogenei… DOI 10.1016/j.csbj.2023.04.003 ↗
Jin Xu · 1 shared paper, 2023 · strength 0.18
- Paper Metabolic reprogramming of cancer-associated fibroblasts in pancreatic cancer contributes to the intratumor heterogenei… DOI 10.1016/j.csbj.2023.04.003 ↗
Si Shi · 1 shared paper, 2023 · strength 0.18
- Paper Metabolic reprogramming of cancer-associated fibroblasts in pancreatic cancer contributes to the intratumor heterogenei… DOI 10.1016/j.csbj.2023.04.003 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.